US FDA grants priority review status to Johnson & Johnson's sBLA for Rybrevant Faspro for adults with recurrent or metastatic HNSCC

Johnson & Johnson announced that the US Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for subcutaneous amivantamab and hyaluronidase─